meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced UC (mUC) - maintenance (M)
mUC - M - all population
1
mUC - M - PDL1 positive
1
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone
versus all
vs non active control
vs BSC
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
avelumab alone
title
BSC
title
JAVELIN Bladder 100 (PDL1>25%), 2020 NCT02603432 mUC - M - PDL1 positive 189/169
Pathology:
mUC - M - PDL1 positive;
mUC - M - PDL1 positive
JAVELIN Bladder 100 (PDL1>25%), 2020
avelumab alone
1
T1
BSC
0
T0